Mipsagargin, a novel thapsigargin-based PSMA-Activated prodrug: Results of a first-in-man phase i clinical trial in patients with refractory, advanced or metastatic solid tumours

D. Mahalingam*, G. Wilding, S. Denmeade, J. Sarantopoulas, D. Cosgrove, J. Cetnar, N. Azad, J. Bruce, M. Kurman, V. E. Allgood, M. Carducci

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

70 Scopus citations

Fingerprint Dive into the research topics of 'Mipsagargin, a novel thapsigargin-based PSMA-Activated prodrug: Results of a first-in-man phase i clinical trial in patients with refractory, advanced or metastatic solid tumours'. Together they form a unique fingerprint.

Medicine & Life Sciences